Production (Stage)
Ginkgo Bioworks Holdings, Inc.
DNA
$7.42
$0.639.28%
NYSE
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.20% | -50.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.20% | -50.76% | |||
| Cost of Revenue | 25.20% | -19.84% | |||
| Gross Profit | 5.98% | -55.58% | |||
| SG&A Expenses | -5.66% | -0.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.22% | -2.35% | |||
| Operating Income | 6.54% | -80.15% | |||
| Income Before Tax | 15.75% | -89.97% | |||
| Income Tax Expenses | 127.08% | 13.33% | |||
| Earnings from Continuing Operations | 15.42% | -90.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.42% | -90.65% | |||
| EBIT | 6.54% | -80.15% | |||
| EBITDA | 7.48% | -123.69% | |||
| EPS Basic | 16.08% | -85.07% | |||
| Normalized Basic EPS | 5.35% | -108.84% | |||
| EPS Diluted | 15.92% | -85.00% | |||
| Normalized Diluted EPS | 5.35% | -108.84% | |||
| Average Basic Shares Outstanding | 0.79% | 3.01% | |||
| Average Diluted Shares Outstanding | 0.79% | 3.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||